Insulin degludec may be considered during pregnancy: CDSCO Panel tells Novo Nordisk
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to drug major Novo-Nordisk to update the prescribing information of the antidiabetic Insulin degludec solution 100U/ml and 200U/ml which stated that the treatment with Insulin degludec may be considered during pregnancy, if clinically needed.
This came after the firm presented the proposal for the update in the prescribing information of the antidiabetic drug Insulin degludec.
At the recent SEC meeting for Endocrinology & Metabolism held on January 19th & 20th 2022, the expert panel reviewed the proposal for the update in the prescribing information of the antidiabetic drug Insulin degludec solution 100U/ml and 200U/ml.
After detailed deliberation, the committee recommended to include the following in the prescribing information of the drug in the section of use in special populations: “The treatment with Insulin degludec may be considered during pregnancy, if clinically needed”.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.